康辰藥業(603590.SH):撤回地拉羅司分散片藥品註冊申請並獲批准
格隆匯7月26日丨康辰藥業(603590.SH)公佈,近日,公司收到國家藥品監督管理局關於公司主動申請撤回地拉羅司分散片註冊申請的《藥品註冊申請終止通知書》。
根據諾華財報顯示,地拉羅司分散片2020年的全球銷售額為6.53億美元;PDB數據庫顯示,地拉羅司分散片2020年國內樣本醫院銷售額為1973萬元人民幣;國家藥監局數據庫顯示,國內已有江蘇奧賽康藥業有限公司和MSN Laboratories Private Limited申報生產,目前未見獲批上市信息。
截至公吿日,公司在該產品上已投入的研發費用約2196萬元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.